ibsrela
Generic: TENAPANOR HYDROCHLORIDE
ibsrela: sourced relationships with 1 company · 1 FDA decision.
ibsrela evidence translation
What we can confirm
1 FDA record
What it means
Source-backed records connect ibsrela to ARDX; that link alone does not prove the drug works.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
How could ibsrela → ARDX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Irritable bowel syndrome with constipation (IBS-C) in adults
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ARDELYX, INC. (ARDX) Irritable bowel syndrome with constipation (IBS-C) in adults | Approved |
FDA Decisions1 records
NDA211801Type 1 - New Molecular EntityStandardOralTablet
Frequently asked questions
Which companies have sourced relationships with ibsrela?
ibsrela has dated SEC/FDA relationship records for ARDELYX, INC..
What is ibsrela's latest FDA decision?
The most recent tracked FDA decision for ibsrela is Approval for 1 INDICATIONS AND USAGE IBSRELA is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is a sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. ( 1 ), dated September 12, 2019.